XML 86 R30.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Restructuring and Asset Impairment Charges (Tables) | 9 Months Ended
--- | ---
Dec. 31, 2019
Restructuring and Related Activities [Abstract] |
Restructuring, Impairment and Related Costs | Restructuring, Impairment and Related Charges for the Company’s fiscal 2019 initiatives during the three and nine months ended December 31, 2019 consisted of the following:
| Three Months Ended December 31, 2019
(In millions) | U.S. Pharmaceutical and Specialty Solutions |  | European Pharmaceutical Solutions |  | Medical-Surgical Solutions |  | Other |  | Corporate |  | Total
Severance and employee-related costs, net | $ | 3 |  |  | $ | 1 |  |  | $ | 1 |  |  | $ | — |  |  | $ | 7 |  |  | $ | 12 |
Exit and other-related costs (1) | — |  |  | 2 |  |  | 5 |  |  | — |  |  | 13 |  |  | 20 |
Asset impairments and accelerated depreciation | — |  |  | 2 |  |  | — |  |  | — |  |  | 3 |  |  | 5 |
Total | $ | 3 |  |  | $ | 5 |  |  | $ | 6 |  |  | $ | — |  |  | $ | 23 |  |  | $ | 37 |
| Nine Months Ended December 31, 2019
(In millions) | U.S. Pharmaceutical and Specialty Solutions |  | European Pharmaceutical Solutions |  | Medical-Surgical Solutions |  | Other |  | Corporate |  | Total
Severance and employee-related costs, net | $ | 4 |  |  | $ | 3 |  |  | $ | 2 |  |  | $ | 1 |  |  | $ | 23 |  |  | $ | 33 |
Exit and other-related costs (1) | — |  |  | 7 |  |  | 9 |  |  | 1 |  |  | 36 |  |  | 53 |
Asset impairments and accelerated depreciation | — |  |  | 8 |  |  | 1 |  |  | — |  |  | 8 |  |  | 17 |
Total | $ | 4 |  |  | $ | 18 |  |  | $ | 12 |  |  | $ | 2 |  |  | $ | 67 |  |  | $ | 103 |
(1) | Exit and other-related costs primarily include project consulting fees.
Restructuring, impairment and related charges for the Company’s fiscal 2019 initiatives during the three and nine months ended December 31, 2018 consisted of the following:
| Three Months Ended December 31, 2018
(In millions) | U.S. Pharmaceutical and Specialty Solutions |  | European Pharmaceutical Solutions |  | Medical-Surgical Solutions |  | Other |  | Corporate |  | Total
Severance and employee-related costs, net | $ | 1 |  |  | $ | — |  |  | $ | — |  |  | $ | 9 |  |  | $ | 32 |  |  | $ | 42 |
Exit and other-related costs (1) | 1 |  |  | 4 |  |  | 5 |  |  | — |  |  | 16 |  |  | 26 |
Asset impairments and accelerated depreciation | 2 |  |  | — |  |  | 1 |  |  | — |  |  | — |  |  | 3 |
Total | $ | 4 |  |  | $ | 4 |  |  | $ | 6 |  |  | $ | 9 |  |  | $ | 48 |  |  | $ | 71 |
| Nine Months Ended December 31, 2018
(In millions) | U.S. Pharmaceutical and Specialty Solutions |  | European Pharmaceutical Solutions |  | Medical-Surgical Solutions |  | Other |  | Corporate |  | Total
Severance and employee-related costs, net | $ | 4 |  |  | $ | — |  |  | $ | 10 |  |  | $ | 16 |  |  | $ | 36 |  |  | $ | 66 |
Exit and other-related costs (1) | 7 |  |  | 4 |  |  | 12 |  |  | 56 |  |  | 45 |  |  | 124 |
Asset impairments and accelerated depreciation | 6 |  |  | — |  |  | 2 |  |  | 17 |  |  | — |  |  | 25 |
Total | $ | 17 |  |  | $ | 4 |  |  | $ | 24 |  |  | $ | 89 |  |  | $ | 81 |  |  | $ | 215 |
(1) Exit and other-related costs primarily include lease exit costs associated with closures of retail pharmacy stores within the Company’s Canadian business as well as project consulting fees.
Schedule of Restructuring and Asset Impairment Charges | The following table summarizes the activity related to the restructuring liabilities associated with the Company’s fiscal 2019 initiatives for the nine months ended December 31, 2019:
(In millions) | U.S. Pharmaceutical and Specialty Solutions |  | European Pharmaceutical Solutions |  | Medical-Surgical Solutions |  | Other |  | Corporate |  | Total
Balance, March 31, 2019 (1) | $ | 31 |  |  | $ | 38 |  |  | $ | 15 |  |  | $ | 29 |  |  | $ | 37 |  |  | $ | 150 |
Restructuring, impairment and related charges | 4 |  |  | 18 |  |  | 12 |  |  | 2 |  |  | 67 |  |  | 103 |
Non-cash charges | — |  |  | (8 | ) |  | (1 | ) |  | — |  |  | (8 | ) |  | (17 | )
Cash payments | (6 | ) |  | (13 | ) |  | (8 | ) |  | (16 | ) |  | (43 | ) |  | (86 | )
Other | (1 | ) |  | (4 | ) |  | (2 | ) |  | (5 | ) |  | (6 | ) |  | (18 | )
Balance, December 31, 2019 (2) | $ | 28 |  |  | $ | 31 |  |  | $ | 16 |  |  | $ | 10 |  |  | $ | 47 |  |  | $ | 132 |
(1) | As of March 31, 2019, the total reserve balance was $150 million of which $117 million was recorded in other accrued liabilities and $33 million was recorded in other noncurrent liabilities.
(2) As of December 31, 2019, the total reserve balance was $132 million of which $110 million was recorded in other accrued liabilities and $22 million was recorded in other noncurrent liabilities.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(2)) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration